[The long-term effects of colestipol hydrochloride on serum and lipoprotein lipids in patients with heterozygous familial hypercholesterolemia (author's transl)]. 1981

T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011073 Polyamines Amine compounds that consist of carbon chains or rings containing two or more primary amino groups. Polyamine
D003084 Colestipol Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels. Colestid,Colestipol HCl,Colestipol Hydrochloride,U-26,597 A,HCl, Colestipol,Hydrochloride, Colestipol,U 26,597 A,U26,597 A
D005260 Female Females
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic

Related Publications

T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
January 1983, Acta paediatrica Scandinavica,
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
January 1975, Clinical pharmacology and therapeutics,
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
January 1975, Giornale italiano di cardiologia,
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
March 1992, Casopis lekaru ceskych,
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
January 1986, European journal of clinical pharmacology,
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
August 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
October 1980, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
February 1978, Atherosclerosis,
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
January 1989, Arteriosclerosis (Dallas, Tex.),
T Wakasugi, and T Sakai, and A Watanabe, and R Tatami, and K Ueda, and R Ueda, and T Kametani, and T Haba, and J Koizumi, and S Miyamoto, and H Mabuchi, and R Takeda, and Y Sakai, and A Yoshimura, and T Takegoshi, and M Ohta, and S Ono, and T Ohka, and H Takeshita
January 1982, Kokyu to junkan. Respiration & circulation,
Copied contents to your clipboard!